[{"text": "The magenta ball-stick ( located just above the gefitinib molecule in the active site ) indicates the gatekeeper residue ( threonine790 ) that is commonly mutated to methionine ( T790M ) , resulting in reduced inhibitor binding and drug resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [48, 57], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [179, 184], "tok_span": [40, 44]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [179, 184], "obj_char_span": [48, 57], "rel_type": "resistance or non-response", "sbj_tok_span": [40, 44], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "We also found gefitinib or NK cells could enhance MHC-I expression , which impairs the recognization of NK cells , in lung tumor cells with wild type EGFR , while not in those with EGFR L858R + T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [14, 23], "tok_span": [3, 7]}, {"name": "T790M", "ent_type": "variant", "char_span": [194, 199], "tok_span": [46, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [186, 191], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [194, 199], "obj_char_span": [14, 23], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [3, 7]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [186, 191], "obj_char_span": [14, 23], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "MiR-200c could upregulate the expression of E-cadherin and trigger MET in H1975 , but can not reverse the resistance to gefitinib owing to T790M existence .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [120, 129], "tok_span": [31, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [139, 144], "tok_span": [37, 41]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [139, 144], "obj_char_span": [120, 129], "rel_type": "resistance or non-response", "sbj_tok_span": [37, 41], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "Cases Age ( yr ) Sex PS Histology EGFR gene Smoking status Previous chemotherapy regimen Previous gefitinib ( length of PFS ) Previous WBRT 1 59 F 3 Ad NE Never 3 Yes ( 10 months ) Yes 2 82 F 4 Ad Wild type Never 0 No No 3 70 F 3 Ad Wild type Never 1 No Yes 4 86 F 3 Ad Ex 21 ; L858R Never 1 Yes ( 7 months ) No 5 67 F 1 Ad Ex 21 ; L858R Never 1 No No 6 72 M 0 Ad Ex 21 ; L858R Former 1 No No 7 81 M 1 Ad Ex 19 deletion Former 1 Yes ( 46 months ) Yes 8 85 F 2 Ad Ex 21 ; L858R Never 1 No Yes a 66 F 1 Ad Ex 21 ; L858R Never 3 No Yes", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [98, 107], "tok_span": [18, 22]}, {"name": "L858R", "ent_type": "variant", "char_span": [278, 283], "tok_span": [74, 78]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [278, 283], "obj_char_span": [98, 107], "rel_type": "sensitivity", "sbj_tok_span": [74, 78], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "In the IRESSA Pan-Asia Study ( IPASS ) study , eleven treatment-naïve patients had an exon 20 T790M mutation : four had coexisting exon 19 deletions and three had coexisting L858R mutations .", "entity_list": [{"name": "IRESSA", "ent_type": "drug", "char_span": [7, 13], "tok_span": [2, 5]}, {"name": "20 T790M", "ent_type": "variant", "char_span": [91, 99], "tok_span": [23, 28]}, {"name": "coexisting L858R", "ent_type": "variant", "char_span": [163, 179], "tok_span": [40, 46]}], "relation_list": [{"subject": "20 T790M", "object": "IRESSA", "sbj_char_span": [91, 99], "obj_char_span": [7, 13], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 28], "obj_tok_span": [2, 5]}, {"subject": "coexisting L858R", "object": "IRESSA", "sbj_char_span": [163, 179], "obj_char_span": [7, 13], "rel_type": "sensitivity", "sbj_tok_span": [40, 46], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Afatinib was more potent than gefitinib , erlotinib , and lapatinib in inducing the cell death of NSCLC cell lines , including those harboring wild-type EGFR , and the erlotinib-resistant T790M mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [42, 51], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [188, 193], "tok_span": [46, 50]}, {"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [168, 187], "tok_span": [40, 46]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [188, 193], "obj_char_span": [42, 51], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [11, 15]}, {"subject": "T790M", "object": "erlotinib-resistant", "sbj_char_span": [188, 193], "obj_char_span": [168, 187], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [40, 46]}], "umls_entity_list": []}, {"text": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original L858R EGFR was inhibited by lower concentrations of gefitinib or erlotinib than the L858R-L747S or L858R-T790M constructs ( A ) . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [112, 117], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [112, 117], "obj_char_span": [177, 186], "rel_type": "sensitivity", "sbj_tok_span": [17, 21], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "Activating mutations such as exon 21 missense point mutation L858R and in-frame deletions in exon 19 are the most commonly studied predictive biomarkers of response to EGFR-TKIs ( gefitinib and erlotinib ) , . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [194, 203], "tok_span": [43, 47]}, {"name": "L858R", "ent_type": "variant", "char_span": [61, 66], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [61, 66], "obj_char_span": [194, 203], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "A non-small-cell lung cancer cell line bearing both T790M and L858R mutations was approximately 100-fold less sensitive to gefitinib or erlotinib , and did not show inhibition of tyrosine phosphorylation in vitro .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [136, 145], "tok_span": [35, 39]}, {"name": "L858R", "ent_type": "variant", "char_span": [62, 67], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [52, 57], "tok_span": [12, 16]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [62, 67], "obj_char_span": [136, 145], "rel_type": "sensitivity", "sbj_tok_span": [17, 21], "obj_tok_span": [35, 39]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [52, 57], "obj_char_span": [136, 145], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "B ) , suggesting the anti-tumor effect of cetuximab against tumors harboring EGFR G719S mutant .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [42, 51], "tok_span": [10, 14]}, {"name": "G719S", "ent_type": "variant", "char_span": [82, 87], "tok_span": [18, 22]}], "relation_list": [{"subject": "G719S", "object": "cetuximab", "sbj_char_span": [82, 87], "obj_char_span": [42, 51], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Taken together , these data suggest that colon cancer derived cetuximab-sensitive G719S and G724S mutants acquire their oncogenic potentials following asymmetric dimerization , respectively , which are similar to lung-cancer derived L858R mutant .", "entity_list": [{"name": "cetuximab-sensitive", "ent_type": "drug", "char_span": [62, 81], "tok_span": [10, 16]}, {"name": "G719S", "ent_type": "variant", "char_span": [82, 87], "tok_span": [16, 20]}, {"name": "G724S", "ent_type": "variant", "char_span": [92, 97], "tok_span": [21, 25]}], "relation_list": [{"subject": "G719S", "object": "cetuximab-sensitive", "sbj_char_span": [82, 87], "obj_char_span": [62, 81], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [10, 16]}, {"subject": "G724S", "object": "cetuximab-sensitive", "sbj_char_span": [92, 97], "obj_char_span": [62, 81], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [10, 16]}], "umls_entity_list": []}, {"text": "Recently , the addition of cetuximab to afatinib has yielded impressive results in the treatment of EGFR reversible TKI resistant lung cancer due to T790M mutation .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [27, 36], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [149, 154], "tok_span": [29, 33]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [149, 154], "obj_char_span": [27, 36], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Acquired resistance EGFR mutations Mutations in the EC domain ( S492R ) and in the kinase domain ( codons 714 and 794 ) of EGFR found in patients Panitumumab remained active in a patient with S492R mutation , which abrogated cetuximab binding .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [225, 234], "tok_span": [53, 57]}, {"name": "S492R", "ent_type": "variant", "char_span": [64, 69], "tok_span": [11, 15]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [64, 69], "obj_char_span": [225, 234], "rel_type": "resistance", "sbj_tok_span": [11, 15], "obj_tok_span": [53, 57]}], "umls_entity_list": []}, {"text": "In the one case of discordance between KRAS mutation status before and after combined cetuximab therapy ( case # 4 ) , a mutated KRAS gene ( Exon 2 G12D ) was found in the primary CRC , while no KRAS mutation was observed in a liver metastasis sample obtained after combined cetuximab therapy ( ) .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [86, 95], "tok_span": [16, 20]}, {"name": "G12D", "ent_type": "variant", "char_span": [148, 152], "tok_span": [36, 39]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [275, 284], "tok_span": [62, 66]}], "relation_list": [{"subject": "G12D", "object": "cetuximab", "sbj_char_span": [148, 152], "obj_char_span": [86, 95], "rel_type": "sensitivity", "sbj_tok_span": [36, 39], "obj_tok_span": [16, 20]}, {"subject": "G12D", "object": "cetuximab", "sbj_char_span": [148, 152], "obj_char_span": [275, 284], "rel_type": "sensitivity", "sbj_tok_span": [36, 39], "obj_tok_span": [62, 66]}], "umls_entity_list": []}, {"text": "The D842V was identified in one patient with primary mutation V561D , which is known to be associated with imatinib resistance .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [107, 115], "tok_span": [25, 27]}, {"name": "D842V", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [4, 9], "obj_char_span": [107, 115], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Afatinib also shows activity against cancers resistant to first-generation EGFR inhibitors due to certain activating EGFR mutations , secondary EGFR mutations such as T790M or tumours expressing other ErbB family receptors activated by drug induced reprogramming of signalling pathways .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "T790M", "ent_type": "variant", "char_span": [167, 172], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "Afatinib", "sbj_char_span": [167, 172], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [26, 30], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Another approach for T790M mediated resistance is the dual inhibition of EGFR with afatinib and cetuximab , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [83, 91], "tok_span": [16, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [21, 26], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [21, 26], "obj_char_span": [83, 91], "rel_type": "response", "sbj_tok_span": [3, 7], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Combination therapy with dasatinib and low-dose decitabine in TET2 mutated SM Next , we exploited the cooperation between loss of function of TET2 and KIT D816V in the HMC-1.2 cell line to validate possible combinatorial approaches to treatment for ASM and MCL , .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [25, 34], "tok_span": [4, 6]}, {"name": "D816V", "ent_type": "variant", "char_span": [155, 160], "tok_span": [37, 41]}], "relation_list": [{"subject": "D816V", "object": "dasatinib", "sbj_char_span": [155, 160], "obj_char_span": [25, 34], "rel_type": "response", "sbj_tok_span": [37, 41], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "These results indicated that co-treatment with ponatinib and vorinostat was effective against T315I mutant cells in the xenograft model ( ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [8, 12]}, {"name": "T315I", "ent_type": "variant", "char_span": [94, 99], "tok_span": [20, 24]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [94, 99], "obj_char_span": [47, 56], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation T790M or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [151, 160], "tok_span": [31, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [99, 104], "tok_span": [20, 24]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [99, 104], "obj_char_span": [151, 160], "rel_type": "resistance or non-response", "sbj_tok_span": [20, 24], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "NSCLC tumors carrying EGFR activating mutations ( e.g. , exon 19 deletions or L858R ) respond preferentially to the EGFR TKIs gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [126, 135], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [78, 83], "tok_span": [16, 20]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [78, 83], "obj_char_span": [126, 135], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "However , EGFR mutations was not a significant prognostic factor in an initial two large retrospective studies in surgically treated patients without gefitinib treatment ( ; ) , although reported that patients with exon 19 deletion have significantly shorter survival than those with L858R , but this is not confirmed by other investigators so far .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [150, 159], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [284, 289], "tok_span": [46, 50]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [284, 289], "obj_char_span": [150, 159], "rel_type": "sensitivity", "sbj_tok_span": [46, 50], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Another seven studies ( clinical trials or retrospective studies ) , , , , , , involving 549 advanced NSCLC patients receiving first-line EGFR-TKIs ( gefitinib or erlotinib ) presented direct comparison of exon 19 deletion and L858R mutation for PFS .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [150, 159], "tok_span": [31, 35]}, {"name": "L858R", "ent_type": "variant", "char_span": [227, 232], "tok_span": [49, 53]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [227, 232], "obj_char_span": [150, 159], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "The L858R mutant was 10–100 fold more sensitive to erlotinib and gefitinib than the wild type kinase , .", "entity_list": [{"name": "and gefitinib", "ent_type": "drug", "char_span": [61, 74], "tok_span": [18, 23]}, {"name": "L858R", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "L858R", "object": "and gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [61, 74], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [18, 23]}], "umls_entity_list": []}, {"text": "The bulkier methionine residue T790M changes the ATP binding pocket of the tyrosine kinase domain , leading to the blockade of gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [140, 149], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [31, 36], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [31, 36], "obj_char_span": [140, 149], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR , cetuximab and panitumumab , in metastatic colon cancer and BRAF V600E mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [137, 148], "tok_span": [24, 27]}, {"name": "V600E", "ent_type": "variant", "char_span": [187, 192], "tok_span": [34, 37]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [187, 192], "obj_char_span": [137, 148], "rel_type": "resistance or non-response", "sbj_tok_span": [34, 37], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Intense research efforts over the past few years have identified two major mechanisms of acquired resistance to gefitinib/erlotinib : secondary resistance mutations ( e.g. , T790M ) and “oncogene kinase switch” systems ( e.g. , MET amplification and AXL activation ) .", "entity_list": [{"name": "gefitinib/erlotinib", "ent_type": "drug", "char_span": [112, 131], "tok_span": [18, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [174, 179], "tok_span": [37, 41]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib", "sbj_char_span": [174, 179], "obj_char_span": [112, 131], "rel_type": "resistance or non-response", "sbj_tok_span": [37, 41], "obj_tok_span": [18, 27]}], "umls_entity_list": []}, {"text": "Due to their ability to potently inhibit EGFR , both afatinib and neratinib have been assessed in lung cancer that has become resistant to gefitinib and erlotinib due to the T790M point mutation in the kinase domain .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [153, 162], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [174, 179], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [174, 179], "obj_char_span": [153, 162], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 45], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "The L1196M mutation is hypothesized to induce steric interference of crizotinib binding similar to those in BCR-ABL and EGFR .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [69, 79], "tok_span": [13, 17]}, {"name": "L1196M", "ent_type": "variant", "char_span": [4, 10], "tok_span": [1, 5]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [4, 10], "obj_char_span": [69, 79], "rel_type": "resistance", "sbj_tok_span": [1, 5], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "To further explore the functional consequences of the T790M mutation , we determined the sensitivity of various NSCLC cells lines grown in the presence of either gefitinib or erlotinib , using an assay based upon Calcein AM .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [162, 171], "tok_span": [29, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [54, 59], "tok_span": [8, 12]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [54, 59], "obj_char_span": [162, 171], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 12], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "In this present study , erlotinib- and gefitinib-resistant cell lines were established from two human lung cancer cell lines , PC9 cells harboring delE746-A750 mutation and 11–18 cells harboring L858R mutation , respectively .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [39, 58], "tok_span": [11, 17]}, {"name": "harboring L858R", "ent_type": "variant", "char_span": [185, 200], "tok_span": [47, 52]}], "relation_list": [{"subject": "harboring L858R", "object": "gefitinib-resistant", "sbj_char_span": [185, 200], "obj_char_span": [39, 58], "rel_type": "sensitivity", "sbj_tok_span": [47, 52], "obj_tok_span": [11, 17]}], "umls_entity_list": []}, {"text": "Consistent with the increased sensitivity to gefitinib and erlotinib of patient tumors harboring the missense mutations or exon 19 deletions , anchorage independent growth of cells expressing L858R , G719S , or L747_E749del A750P was inhibited by 100 nM erlotinib ( A and B ) or gefitinib ( B and unpublished data ) , although the G719S mutant may be somewhat more resistant to gefitinib ( A and unpublished data ) , consistent with other in vitro studies .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [45, 54], "tok_span": [6, 10]}, {"name": "G719S", "ent_type": "variant", "char_span": [200, 205], "tok_span": [40, 44]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [279, 288], "tok_span": [73, 77]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [378, 387], "tok_span": [97, 101]}, {"name": "L858R", "ent_type": "variant", "char_span": [192, 197], "tok_span": [35, 39]}], "relation_list": [{"subject": "G719S", "object": "gefitinib", "sbj_char_span": [200, 205], "obj_char_span": [45, 54], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [6, 10]}, {"subject": "G719S", "object": "gefitinib", "sbj_char_span": [200, 205], "obj_char_span": [279, 288], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [73, 77]}, {"subject": "G719S", "object": "gefitinib", "sbj_char_span": [200, 205], "obj_char_span": [378, 387], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [97, 101]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [192, 197], "obj_char_span": [45, 54], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [6, 10]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [192, 197], "obj_char_span": [279, 288], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [73, 77]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [192, 197], "obj_char_span": [378, 387], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [97, 101]}], "umls_entity_list": []}, {"text": "To overcome such drug resistance , novel mutant-selective EGFR kinase inhibitors against EGFR T790M were reported , and 4-pyrrylamino quinazolines as new gefitinib analogues were synthesized .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [154, 163], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [94, 99], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [94, 99], "obj_char_span": [154, 163], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "Recent report by Yoshikawa , S. et al. ( 2013 ) demonstrated the acquired resistant of double mutant G719S/T790M (DM) to gefitinib , G719S mutation occurs within the phosphate binding loop ( P-loop ) and not observed frequently .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [34, 38]}, {"name": "G719S", "ent_type": "variant", "char_span": [133, 138], "tok_span": [39, 43]}], "relation_list": [{"subject": "G719S", "object": "gefitinib", "sbj_char_span": [133, 138], "obj_char_span": [121, 130], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "PC9GR cells ( gefitinib resistant ) were shown to harbor a secondary T790M mutation in EGFR , whereas HCC827ER cells ( erlotinib resistant ) demonstrated MET overexpression , as previously reported ( ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [119, 128], "tok_span": [32, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [69, 74], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [69, 74], "obj_char_span": [119, 128], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "An experiment using cell lines transfected concurrently with activating mutations and a T790M mutation also proved that resistance to gefitinib and erlotinib is evident when this mutation is present .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [148, 157], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [88, 93], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [88, 93], "obj_char_span": [148, 157], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Erlotinib is particularly effective in cancers in which the EGFR kinase domain contains activating mutations , the two most common of which are Δ746–750 and L858R– .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "and L858R–", "ent_type": "variant", "char_span": [153, 163], "tok_span": [30, 36]}], "relation_list": [{"subject": "and L858R–", "object": "Erlotinib", "sbj_char_span": [153, 163], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [30, 36], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Further , patients with nonsmall cell lung cancer who initially responded to erlotinib or gefitinib therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of erlotinib or gefitinib would lead to a surge in the rate of EGFR T790M mutation which , in vitro , conferred resistance to treatment with erlotinib and gefitinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [77, 86], "tok_span": [14, 18]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [315, 325], "tok_span": [67, 72]}, {"name": "of erlotinib", "ent_type": "drug", "char_span": [252, 264], "tok_span": [48, 53]}, {"name": "with erlotinib", "ent_type": "drug", "char_span": [388, 402], "tok_span": [83, 88]}], "relation_list": [{"subject": "EGFR T790M", "object": "erlotinib", "sbj_char_span": [315, 325], "obj_char_span": [77, 86], "rel_type": "resistance or non-response", "sbj_tok_span": [67, 72], "obj_tok_span": [14, 18]}, {"subject": "EGFR T790M", "object": "of erlotinib", "sbj_char_span": [315, 325], "obj_char_span": [252, 264], "rel_type": "resistance or non-response", "sbj_tok_span": [67, 72], "obj_tok_span": [48, 53]}, {"subject": "EGFR T790M", "object": "with erlotinib", "sbj_char_span": [315, 325], "obj_char_span": [388, 402], "rel_type": "resistance or non-response", "sbj_tok_span": [67, 72], "obj_tok_span": [83, 88]}], "umls_entity_list": []}, {"text": "What is remarkable is that the H1975 cell line harbors the T790M and L858R mutations in the HER1 gene ( information obtained from the Sanger Institute website ) , which confer resistance to HER1 kinase inhibitors , Gefitinib and Erlotinib , responded to the irreversible HER1 kinase inhibitor BIBW-2992 . ", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [229, 238], "tok_span": [53, 56]}, {"name": "L858R", "ent_type": "variant", "char_span": [69, 74], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [59, 64], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [69, 74], "obj_char_span": [229, 238], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [53, 56]}, {"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [59, 64], "obj_char_span": [229, 238], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [53, 56]}], "umls_entity_list": []}, {"text": "C1156Y EML-ALKpm Alters ALK crizotinib binding cavity , reducing crizotinib-protein interactions", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [28, 38], "tok_span": [14, 18]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}, {"name": "crizotinib-protein", "ent_type": "drug", "char_span": [65, 83], "tok_span": [22, 28]}], "relation_list": [{"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [28, 38], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [14, 18]}, {"subject": "C1156Y", "object": "crizotinib-protein", "sbj_char_span": [0, 6], "obj_char_span": [65, 83], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [22, 28]}], "umls_entity_list": []}, {"text": "Ph II ; randomized , single-arm n = 129 ; Taiwanese and US ; chemo-naïve , or one previous line of chemotherapy ; exon 19 deletion ( n = 52 ) ; L858R ( n = 54 ) ; other ( n = 23 ) Afatinib 40 mg or 50 mg/day PFS : 14 months", "entity_list": [{"name": "; L858R", "ent_type": "variant", "char_span": [142, 149], "tok_span": [36, 41]}, {"name": ") Afatinib", "ent_type": "drug", "char_span": [178, 188], "tok_span": [52, 55]}], "relation_list": [{"subject": "; L858R", "object": ") Afatinib", "sbj_char_span": [142, 149], "obj_char_span": [178, 188], "rel_type": "sensitivity", "sbj_tok_span": [36, 41], "obj_tok_span": [52, 55]}], "umls_entity_list": []}, {"text": "Two phase III trials compared afatinib to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 L858R point mutation ) . ", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [30, 38], "tok_span": [5, 7]}, {"name": "L858R", "ent_type": "variant", "char_span": [265, 270], "tok_span": [51, 55]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [265, 270], "obj_char_span": [30, 38], "rel_type": "sensitivity", "sbj_tok_span": [51, 55], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "AP-24534 and XL-228 have demonstrated activity in cell culture and in mice bearing xenograft tumors expressing T315I BCR-ABL mutants .", "entity_list": [{"name": "AP-24534", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 4]}, {"name": "T315I", "ent_type": "variant", "char_span": [111, 116], "tok_span": [22, 26]}], "relation_list": [{"subject": "T315I", "object": "AP-24534", "sbj_char_span": [111, 116], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Therapy of NSCLC with first generation small molecule EGFR kinase inhibitors , gefitinib and erlotinib , is severely limited by two main factors : first , the poor sensitivity to TKIs of tumor cells expressing wild type forms of the receptor ; second the emergence of drug resistance in virtually all tumors bearing EGFR mutations initially sensitive for the presence of either exon 19 deletions or exon 21 mutation L858R .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [93, 102], "tok_span": [17, 21]}, {"name": "L858R", "ent_type": "variant", "char_span": [416, 421], "tok_span": [76, 80]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [416, 421], "obj_char_span": [93, 102], "rel_type": "sensitivity", "sbj_tok_span": [76, 80], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "H358 and H441 cells expressing WT EGFR or H1975 cells expressing L858R and T790M mutant EGFR were left untreated ( NT ) or treated for 24 h with gefitinib ( 10 , 2 , 0.4 , 0.08 μM ) or DMSO ( D ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [145, 154], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [75, 80], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [65, 70], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [75, 80], "obj_char_span": [145, 154], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 26], "obj_tok_span": [40, 44]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [65, 70], "obj_char_span": [145, 154], "rel_type": "sensitivity", "sbj_tok_span": [17, 21], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "Second-generation irreversible EGFR inhibitors , which bind irreversibly in the ATP binding pocket of EGFR through a covalent bond at C797 , were shown to be more potent inhibitors of the second-site T790M mutation than erlotinib or gefitinib in pre-clinical models ( ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [233, 242], "tok_span": [50, 54]}, {"name": "T790M", "ent_type": "variant", "char_span": [200, 205], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [200, 205], "obj_char_span": [233, 242], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [50, 54]}], "umls_entity_list": []}, {"text": "Sensitive detection methods have identified a proportion of tyrosin- kinase- naive tumors that carry T790M , a resistant tumor cell clones that may be selected during the exposure to gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [183, 192], "tok_span": [37, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [101, 106], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [101, 106], "obj_char_span": [183, 192], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "OPTIMAL People’s Republic of China Erlotinib ( 82 ) versus CBDCA plus GEM ( 72 ) Exon 19 deletion or L858R", "entity_list": [{"name": "China Erlotinib", "ent_type": "drug", "char_span": [29, 44], "tok_span": [8, 12]}, {"name": "or L858R", "ent_type": "variant", "char_span": [98, 106], "tok_span": [29, 34]}], "relation_list": [{"subject": "or L858R", "object": "China Erlotinib", "sbj_char_span": [98, 106], "obj_char_span": [29, 44], "rel_type": "sensitivity", "sbj_tok_span": [29, 34], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "For example , patients with epidermal growth factor receptor (EGFR) mutations , most frequently exon 19 deletions and exon 21 point mutation L858R may respond to EGFR–TKI , like gefitinib or erlotinib .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [188, 200], "tok_span": [41, 46]}, {"name": "L858R", "ent_type": "variant", "char_span": [141, 146], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "or erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [188, 200], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [41, 46]}], "umls_entity_list": []}, {"text": "PDGFRA mutation T674I confers imatinib resistance .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [30, 38], "tok_span": [8, 10]}, {"name": "T674I", "ent_type": "variant", "char_span": [16, 21], "tok_span": [3, 7]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [16, 21], "obj_char_span": [30, 38], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "The T315I mutation experiences increased ( −4.11 kcal/mol ) and T315A mutation experiences decreased electrostatic interactions ( −2.05 kcal/mol ) , and the mutation G250E contributes increased electrostatic interaction ( −0.32 kcal/mol ) while binding to ponatinib .", "entity_list": [{"name": "to ponatinib", "ent_type": "drug", "char_span": [253, 265], "tok_span": [55, 60]}, {"name": "T315I", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T315I", "object": "to ponatinib", "sbj_char_span": [4, 9], "obj_char_span": [253, 265], "rel_type": "response", "sbj_tok_span": [1, 5], "obj_tok_span": [55, 60]}], "umls_entity_list": []}, {"text": "Ponatinib is a potent BCR-ABL inhibitor with activity against the T315I mutation.", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [66, 71], "tok_span": [14, 18]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [66, 71], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Notably , the T315I Bcr-Abl mutation does not respond to any approved TKI in vitro or clinically , except ponatinib which was approved by US FDA more recently .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [106, 115], "tok_span": [27, 31]}, {"name": "T315I", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [14, 19], "obj_char_span": [106, 115], "rel_type": "response", "sbj_tok_span": [3, 7], "obj_tok_span": [27, 31]}], "umls_entity_list": []}]